Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Second primary malignancies after tandem autoSCT in patients with multiple myeloma

Samer Al Hadidi • 29 Sep 2023
IMS 2023
Multiple Myeloma

Samer Al Hadidi, MD, University of Arkansas for Medical Sciences, Little Rock, AR, discusses the results of a study evaluating the occurrence of second primary malignancies in patients with multiple myeloma treated with tandem autologous stem cell transplantation (autoSCT). This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Samer Al Hadidi

1:22
Risk of infection in patients with multiple myeloma treated with bispecific antibodies
Samer Al Hadidi • 29 Sep 2023

Related Videos

4:24
Investigating production failure and out-of-specification production of CAR T-cell therapeutics
Nina Worel • 25 Apr 2024
1:14
Using MRD to accelerate drug approval in multiple myeloma
Karthik Ramasamy • 28 Apr 2024
3:54
Cilta-cel as a potential new SoC for R/R multiple myeloma: insights from the CARTITUDE-4 trial
Roberto Mina • 23 Apr 2024
1:41
CRS and neurotoxicity in bispecific antibody and CAR-T therapy for multiple myeloma
Eden Biltibo • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals